Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized controlled study in which subjects are assigned to either a treatment group or a control (sham) group. Pre- and post-study outcome measures evaluate the change in incontinence episodes on women with mild-moderate stress urinary incontinence.
The Elitone device delivers electrical muscle stimulation to pelvic floor muscles through a disposable surface electrode shaped to fit the perineal region. In typical use women self-administer treatment 20 minutes per day, 5x per week, for 6-12 weeks. Elidah is initiating a prospective, randomized clinical study to demonstrate device efficacy. The study expands a similar pilot to 60 subjects, adds a control arm (sham device) and includes additional outcome measures. Like the earlier study, subjects will self-administer treatment over multiple weeks while maintaining daily logs of their treatment and incontinence symptoms. This is a home-use study, which does not require clinic visits. Accordingly, this allows subject recruitment from across US.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment | Experimental | Elitone Surface electrical stimulation with a treatment waveform (medium frequency modulated at 50Hz) |
|
| Control | Sham Comparator | Elitone Sham surface electrical stimulation at a very low frequency not known to contract muscles. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transcutaneous electrical stimulation (Elitone) | Device | Transcutaneous perineal area electrical stimulation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy Assessed by Percent Reduction in Urinary Incontinence Episodes | The percent reduction in average number of urinary incontinence episodes over 12 weeks. | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy Assessed by Percent Reduction in Average Pad Weight | The percent reduction of pad weight in a day over the 12 weeks. | 12 weeks |
| Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL) |
Not provided
Inclusion Criteria:
Predominant Mild-moderate stress incontinence symptoms as determined by self-reported typical number of accidents of 1 per 24 hours or more.
Exclusion Criteria:
Yes must identify as female
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nationwide At-Home study | Monroe | Connecticut | 06468 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Treatment | Elitone Surface electrical stimulation with a treatment waveform (medium frequency modulated at 50Hz) Transcutaneous electrical stimulation (Elitone): Transcutaneous perineal area electrical stimulation |
| FG001 | Control | Elitone Sham surface electrical stimulation at a very low frequency not known to contract muscles. Transcutaneous electrical stimulation (Elitone): Transcutaneous perineal area electrical stimulation |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Completed Intervetion |
|
| |||||||||||||||||||||
| Included in Analysis |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Treatment | Elitone Surface electrical stimulation with a treatment waveform (medium frequency modulated at 50Hz) Transcutaneous electrical stimulation (Elitone): Transcutaneous perineal area electrical stimulation |
| BG001 | Control |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Efficacy Assessed by Percent Reduction in Urinary Incontinence Episodes | The percent reduction in average number of urinary incontinence episodes over 12 weeks. | Posted | Mean | Standard Deviation | percent reduction in leaks/day | 12 weeks |
|
Duration of the 12-week study
External elextrical muscle stimulation is a non-significant risk treatment. Accordingly, serious adverse events are not anticipated for a study of this size.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Treatment | Elitone Surface electrical stimulation with a treatment waveform (medium frequency modulated at 50Hz) Transcutaneous electrical stimulation (Elitone): Transcutaneous perineal area electrical stimulation |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Transient muscle pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director of Clinical Trials | Elidah, Inc. | 978.435.4324 | customercare@elitone.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jul 19, 2018 | Nov 26, 2024 | Prot_SAP_001.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014550 | Urinary Incontinence, Stress |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D004561 | Transcutaneous Electric Nerve Stimulation |
| ID | Term |
|---|---|
| D004599 | Electric Stimulation Therapy |
| D013812 | Therapeutics |
| D026741 | Physical Therapy Modalities |
| D012046 | Rehabilitation |
Not provided
Not provided
Randomization
Not provided
Not provided
The device looks identical, but the waveform is different. Randomization, programming and recording of which waveform is done by a third party separate from those listed above.
The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). It comprises 22 questions, to which the subject provides a numeric response on a 1-5 scale. 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The score is the sum of the numeric responses, which can range from 22 to 110. The lower the value the less times it happens and the better outcome.
| 12 weeks |
| Pads Per Day | Reduction of number of pads used per day | 12 weeks |
| NOT COMPLETED |
|
|
Elitone Sham surface electrical stimulation at a very low frequency not known to contract muscles.
Transcutaneous electrical stimulation (Elitone): Transcutaneous perineal area electrical stimulation
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Stress incontinence leaks/day | Mean | Standard Deviation | leaks/day |
|
|
|
| Secondary | Efficacy Assessed by Percent Reduction in Average Pad Weight | The percent reduction of pad weight in a day over the 12 weeks. | Posted | Mean | Standard Deviation | percentage reduction in pad weight | 12 weeks |
|
|
|
| Secondary | Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL) | The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). It comprises 22 questions, to which the subject provides a numeric response on a 1-5 scale. 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The score is the sum of the numeric responses, which can range from 22 to 110. The lower the value the less times it happens and the better outcome. | Posted | Mean | Standard Deviation | Change of score on a scale | 12 weeks |
|
|
|
| Secondary | Pads Per Day | Reduction of number of pads used per day | Posted | Mean | Standard Deviation | percentage reduction | 12 weeks |
|
|
|
| 0 |
| 35 |
| 0 |
| 35 |
| 1 |
| 35 |
| EG001 | Control | Elitone Sham surface electrical stimulation at a very low frequency not known to contract muscles. Transcutaneous electrical stimulation (Elitone): Transcutaneous perineal area electrical stimulation | 0 | 13 | 0 | 13 | 0 | 13 |
Not provided
Not provided
Not provided
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000698 |
| Analgesia |
| D000760 | Anesthesia and Analgesia |